Taking aspirin every day to prevent heart disease in people aged 70 and older who are otherwise healthy raises their chance of experiencing serious bleeding in the stomach or intestines, from about 1.6% to 2.4% over nearly five years. This finding is from the abstract summary - full study details were not available
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of multiple RCTs in adults aged 70+ would establish whether the increased risk of major GI bleeding from daily aspirin is consistent across populations, dosages, and durations, and quantify the overall risk-benefit ratio for primary prevention.
A systematic review and meta-analysis of all published RCTs comparing daily low-dose aspirin (75–100 mg) versus placebo in adults aged 70+ without cardiovascular disease, with major GI bleeding as a pre-specified primary outcome, using individual participant data to adjust for age, sex, NSAID use, and H. pylori status, and reporting hazard ratios with 95% confidence intervals.
A double-blind RCT would definitively determine whether daily aspirin causes major GI bleeding in healthy older adults by eliminating bias from participant and investigator expectations.
A double-blind, placebo-controlled RCT of 5,000 healthy adults aged 70–79 with no history of GI bleeding, randomized to 100 mg aspirin daily or placebo for 5 years, with primary outcome defined as major GI bleeding (per TIMI criteria) confirmed by endoscopy or imaging, and secondary outcomes including mortality and cardiovascular events.
A prospective cohort study would determine whether aspirin use predicts major GI bleeding in real-world older adults over time, accounting for confounders like NSAID use, alcohol, and comorbidities.
A prospective cohort of 10,000 community-dwelling adults aged 70+ without cardiovascular disease, followed for 10 years, with aspirin use recorded at baseline and annually, and major GI bleeding identified via hospital records and endoscopy, adjusting for age, sex, BMI, NSAID use, and Helicobacter pylori status.
A case-control study would compare prior aspirin exposure in older adults who experienced major GI bleeding versus those who did not, helping identify risk patterns.
A case-control study of 500 older adults (≥70) hospitalized for major GI bleeding and 1,000 matched controls without GI bleeding, with detailed retrospective assessment of aspirin use (dose, duration, timing), NSAID use, and peptic ulcer history via medical records and pharmacy data.
A cross-sectional survey could estimate the prevalence of aspirin use and GI bleeding symptoms in older adults at a single point in time, but cannot determine causality.
A national survey of 20,000 adults aged 70+ assessing current aspirin use and self-reported GI bleeding symptoms (e.g., black stools, vomiting blood) via structured questionnaire, with validation in a subsample via medical records.